On the Record · Genmab A/S
Genmab A/S acquisitions, on the record
The businesses Genmab A/S bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
ProfoundBio, Inc.Word for word“The Company completed the acquisition of ProfoundBio, Inc. (“ProfoundBio”) for USD 1.72 billion (DKK 11.8 billion) on May 21, 2024.” 20-F for 2024 | acquisition | May 21, 2024 | USD 1.72 billion (DKK 11.8 billion) |
Merus N.V.Word for word“On December 12, 2025, we completed the Acquisition of Merus, resulting in Merus becoming a wholly owned subsidiary of Genmab.” 20-F for 2025 | acquisition | December 12, 2025 | — |
Read from Genmab A/S’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-02-17. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.